Search Videos and More
News
New Clinical Tool for Clonal Hematopoiesis Identifies Patients at High Risk for Blood Cancer
A new clinical tool developed by a team of researchers led by the Dana-Farber Cancer Institute pinpoints which Clonal hematopoiesis patients are at highest risk for cancer progression.
News
Study Unravels a Cause of Resistance to Novel Drug in Patients with Acute Leukemia
A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
Podcast
Season 2, Episode 2: Thalidomide and its Second Act in Multiple Myeloma
Momentum isn't always one way. And it's not always constant. Sometimes it shoves you sideways, sometimes it stops you in your tracks. And sometimes only sometimes, it drives you to write one of the most astonishing second acts in all of medicine. That's the story of thalidomide.
Video
Smoldering Multiple Myeloma - A Unique New Approach
When Deidre was diagnosed with a precursor condition to multiple myeloma she enrolled in a brand-new clinical trial being conducted at Dana-Farber Cancer Institute. Deidre and her doctor, Dana-Farber's Irene Ghobrial, MD, explain more in this video.
News
Dana-Farber Led Study Leads to FDA Approval for Next-Generation Drug in Relapsed Chronic Lymphocytic Leukemia
On Thursday, January 19, 2023, the FDA approved zanubrutinib, a next-generation BTK inhibitor for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
News
For Older Patients with Blood Cancer Taking Multiple Medications, New Tool Links Use of Certain Medications to Risk of Frailty
A new tool developed by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital outperforms conventional methods for predicting whether certain medications are likely to lead to frailty in older patients with blood cancers who are taking multiple medications, a study being published online today indicates.
News
In Memoriam: Arthur T. Skarin, MD, Physician-Scientist Instrumental in Building Dana-Farber’s Adult Oncology Program
The Dana-Farber community mourns the passing of Arthur T. Skarin, MD, of Needham, Massachusetts.
Video
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Inhye Ahn, MD, discusses the background and management of chronic lymphocytic leukemia and small lymphocytic lymphoma.
Video
Hodgkin Lymphoma
Ann LaCasce, MD, MMSc, discusses Hodgkin lymphoma and how to approach the different types of Hodgkin patients.
Video
CAR-T Cell Therapy for Lymphoma: Updates and Progress
Caron Jacobson, MD, MMSc, gives updates and shares progress with CAR-T cell therapy for lymphoma.
Symposium
Hematologic Malignancies CME: 2021
The care of patients with hematologic malignancies is evolving rapidly. These video highlights discuss new developments in the diagnosis and treatment of hematologic malignancies presented at the 2021 Annual Meeting of the American Society of Hematology (ASH).
Video
Blood Cancer Research: Clinical Trial Helps Younger Patient
A patient shares her journey getting diagnosed with chronic lymphocytic leukemia in her 30's. Dana-Farber Cancer Institute's Matthew Davids, MD, MMSc, enrolled her on a clinical trial and details the results of that study. The research is now getting presented at ASH21.